Literature DB >> 2789922

Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate.

P O Greiner1, J Zittoun, J Marquet, J M Cheron.   

Abstract

1. A pharmacokinetic study of the natural (-)-isomer of folinic acid ((-)-5 CHOTHF) and of total (-)-folates was performed in 12 healthy subjects after i.v. and oral administration of the racemic form of folinic acid. 2. After a 25 mg i.v. injection, (-)-5 CHOTHF kinetics were described by a biexponential function. The mean steady state volume of distribution (Vss) was 161; systemic and renal clearances averaged 335 and 53 ml min-1, respectively. After the same oral dose, (-)-5 CHOTHF was rapidly absorbed. Plasma concentrations of unchanged drug were much lower than those achieved after i.v. administration but in nine subjects, the disposition kinetics were also biexponential. Absolute bioavailability was only 4% as a consequence of a significant intestinal first pass effect. 3. AUC and t1/2Z values for total (-)-folates were similar after both routes of administration, indicating that the drug was fully absorbed. However the AUC of the active metabolite after i.v. dosage was only half that after oral dosage. 4. The amounts of total (-)-folates excreted in urine after both routes of administration were not significantly different and averaged one third of the dose after 24 h, whereas excretion of (-)-5 CHOTHF was three times less after oral treatment than after parenteral treatment. 5. Oral administration is a more suitable route for folinic acid therapy because more of the active metabolite is produced than after parenteral injection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789922      PMCID: PMC1379947          DOI: 10.1111/j.1365-2125.1989.tb05429.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  IGPHARM: interactive graphic package for pharmacokinetic analysis.

Authors:  C Gomeni; R Gomeni
Journal:  Comput Biomed Res       Date:  1978-08

2.  Serum distribution of citrovorum factor and 5-methyltetrahydrofolate following oral and im administration of calcium leucovorin in normal adults.

Authors:  B M Mehta; A L Gisolfi; D J Hutchison; A Nirenberg; M G Kellick; G Rosen
Journal:  Cancer Treat Rep       Date:  1978-03

3.  High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement.

Authors:  A T Skarin; K S Zuckerman; S W Pitman; D S Rosenthal; W Moloney; E Frei; G P Canellos
Journal:  Blood       Date:  1977-12       Impact factor: 22.113

4.  Effective absorption and utilization of oral formyltetrahydrofolate in man.

Authors:  P F Nixon; J R Bertino
Journal:  N Engl J Med       Date:  1972-01-27       Impact factor: 91.245

5.  A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue.

Authors:  R G Stoller; H G Kaplan; F J Cummings; P Calabresi
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

6.  Intestinal conversion of folinic acid to 5-methyltetrahydrofolate in man.

Authors:  V M Whitehead; R Pratt; A Viallet; B A Cooper
Journal:  Br J Haematol       Date:  1972-01       Impact factor: 6.998

7.  High-dose methotrexate with a safe rescue program.

Authors:  D A Decker; J H Edmonson; G S Gilchrist; J S Kovach; J R Offord; W F Taylor
Journal:  Oncology       Date:  1981       Impact factor: 2.935

Review 8.  High-dose methotrexate with folinic acid rescue.

Authors:  J F Bender; W R Grove; C L Fortner
Journal:  Am J Hosp Pharm       Date:  1977-09

9.  High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.

Authors:  E Frei; R H Blum; S W Pitman; J M Kirkwood; I C Henderson; A T Skarin; R J Mayer; R C Bast; M B Garnick; L M Parker; G P Canellos
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

10.  Absorption of large oral doses of 5-formyltetrahydrofolate in man.

Authors:  J R Kirwan; E M Narebor
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

View more
  7 in total

1.  Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b.

Authors:  M J Czejka; J Schüller; C Weiss; S Bandak; B Meyer; D Simon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

Review 2.  Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.

Authors:  Nikki de Rouw; Berber Piet; Hieronymus J Derijks; Michel M van den Heuvel; Rob Ter Heine
Journal:  Drug Saf       Date:  2021-11-06       Impact factor: 5.606

3.  Pharmacokinetic comparison of leucovorin and levoleucovorin.

Authors:  J Zittoun; A P Tonelli; J Marquet; E De Gialluly; C Hancock; A Yacobi; J B Johnson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Absorption and blood/cellular transport of folate and cobalamin: Pharmacokinetic and physiological considerations.

Authors:  David H Alpers
Journal:  Biochimie       Date:  2015-11-14       Impact factor: 4.079

5.  FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells.

Authors:  George M Ramzy; Laura Boschung; Thibaud Koessler; Céline Delucinge-Vivier; Mylène Docquier; Thomas A McKee; Laura Rubbia-Brandt; Patrycja Nowak-Sliwinska
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

6.  Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer.

Authors:  Aparajita Budithi; Sumeyye Su; Arkadz Kirshtein; Leili Shahriyari
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

7.  Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.

Authors:  Marloes Zoetemelk; George M Ramzy; Magdalena Rausch; Patrycja Nowak-Sliwinska
Journal:  Molecules       Date:  2020-06-04       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.